Ticker | Current Price | % Daily Change | Volume (1,000s) | Average Volumn (1,000s) | Market Cap (Millions) | 1/2/2024 Price | % Change Since Inception 1/2/2024 |
---|---|---|---|---|---|---|---|
TERN | $5.25 | -6.838% | 1,036 | 1,618 | $446 | $6.49 | -19.2% |
Terns Pharmaceuticals, Inc.
1065 East Hillsdale Boulevard
Suite 100
Foster City, CA 94404
United States
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs.